Human |
AHB Recovered |
Isolated CD4+CD25+
|
Suppression of CD8+ cells |
Franzese et al. [68] |
|
CHB |
|
Frequecny (AHB = CHB = Healthy) |
|
|
Healhty subjects |
|
|
|
Human |
AHB Recovered |
Isolated CD4+CD25+
|
Suppression of CD4+ cells |
Stoop et al. [69] |
|
CH-B |
|
Frequency(Chronic > recovered: Chronic > healthy donors) |
|
|
Healthy subjects |
|
|
|
Human |
AH-B |
Isolated CD4+CD25+; FOXP3+ gated liver infiltrating lymphocytes |
Suppression of CD4+ cells |
Xu et al. [70] |
|
CH-B |
|
Frequency(CH-B severe > CHB, CHB severe > AH-B, CH-B severe > healthy donors) |
|
|
Healthy subjects |
|
|
|
Human |
CH-B |
Isolated CD4+ CD25+
|
Suppression of CD4+ cells |
Kondo et al. [23] |
|
Healthy subjects |
|
Chronic = healthy donors |
|
Human |
Treated CH-B |
CD4+ CD25+ CTLA4+ CD45RO+ (FOXP3+) |
Frequency (Treated CHB < CHB) |
Stoop et al. [71] |
|
CH-B |
|
|
|
|
Healthy subjects |
|
|
|
Human |
Recovered AH-B |
Isolated CD4+CD25+; FOXP3+ liver infiltrating lymphocytes |
Suppression of CD4+ cells and CD8+ cells |
Yang et al. [72] |
|
CH-B |
|
Frequency(Chronic asymptomatic > chronic active > resolved = healthy controls) |
|
|
Healthy subjects |
|
|
|
Human |
CH-B |
CD4+CD25+IL7R-
|
sHSP60 enhances Tregs activity via TLR2 signaling |
Kondo et al. [24] |
|
Treated CH-B patients |
|
Frequency (Treated CHB < CHB) |
|
|
Healthy subjects |
|
|
|
Woodchuck hepatits |
Woodchuck hepatitis |
CD4+FOXP3+
|
Frequency (WHV > Control) |
Otano et al. [73] |
HBV model |
|
|
Interleukin-12 Increases Hepatic Tolerogenicity |
|
Mouse |
AdHBV |
CD4+FOXP3+
|
Down-regulating the antiviral activity of effector T cells by limiting cytokine production and cytotoxicity |
Stross et al. [74] |
Human |
HBV-HCC |
CD4+CD25+FOXP3 |
TGF-b-miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment |
Yang et al. [75] |
Human |
CH-B |
CD4+CD25+
|
Frequency (CH-B = Acute on choronic HBV = Healthy) |
Dong et al. [76] |
|
Acute on choric HBV |
|
|
|
|
Healthy |
|
|
|